Comparative analysis of antigen-specific anti-SARS-CoV-2 antibody isotypes in COVID-19 patients

• Published in: bioRxiv
• Main Authors: Fujigaki, Hidetsugu, Inaba, Masato, Osawa, Michiko, Moriyama, Saya, Takahashi, Yoshimasa, Suzuki, Tadaki, Yamase, Kenya, Yoshida, Yukihiro, Yagura, Yo, Oyamada, Takayoshi, Takemura, Masao, Doi, Yohei, Saito, Kuniaki
• Format: Paper
• Language: English
• Published: Cold Spring Harbor Cold Spring Harbor Laboratory Press 04.12.2020
• Subjects: Antibodies; Antigens; Comparative analysis; Coronaviridae; Coronaviruses; COVID-19; Enzyme-linked immunosorbent assay; Immunoglobulin A; Immunoglobulin G; Immunoglobulin M; Isotypes; N protein; Nucleocapsids; Polymerase chain reaction; Proteins; Serological tests; Serology; Severe acute respiratory syndrome coronavirus 2; Trimers
• DOI: 10.1101/2020.12.04.407510

Abstract Serological tests for detection of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in blood are expected to identify individuals who have acquired immunity against SARS-CoV-2 and indication of seroprevalence of SARS-CoV-2 infection. Many serological tests have been developed to detect antibodies against SARS-CoV-2. However, these tests have considerable variations in their specificity and sensitivity, and whether they can predict levels of neutralizing activity is yet to be determined. This study aimed to investigate the kinetics and neutralizing activity of various antigen-specific antibody isotypes against SARS-CoV-2 in serum of coronavirus disease 2019 (COVID-19) patients confirmed via polymerase chain reaction test. We developed IgG, IgM and IgA measurement assays for each antigen, including receptor-binding domain (RBD) of spike (S) protein, S1 domain, full length S protein, S trimer and nucleocapsid (N) domain, based on enzyme-linked immunosorbent assay. The assays of the S protein for all isotypes showed high specificity, while the assays for all isotypes against N protein showed lower specificity. The sensitivity of all antigen-specific antibody isotypes depended on the timing of the serum collection and all of them, except for IgM against N protein, reached more than 90% at 15-21 days post-symptom onset. The best correlation with virus neutralizing activity was found for IgG against RBD (RBD-IgG), and levels of RBD-IgG in sera from four severe COVID-19 patients increased concordantly with neutralizing activity. Our results provide valuable information regarding the selection of serological test for seroprevalence and vaccine evaluation studies. Competing Interest Statement Kenya Yamase, Yukihiro Yoshida, Yo Yagura are employees of FUJIFILM Wako Pure Chemical Corporation. Takayoshi Oyamada is an employee of FUJIFILM Corporation. Other authors declare that they have no conflict of interest.